Akums Drugs and Pharmaceuticals Limited (IN:AKUMS)
:AKUMS
Want to see IN:AKUMS full AI Analyst Report?
AKUMS Stock Chart & Stats
₹420.10
₹13.30(2.17%)
At close: 4:00 PM EST
₹420.10
₹13.30(2.17%)
Day’s Range― - ―
52-Week Range₹410.10 - ₹633.55
Previous CloseN/A
Volume56.90K
Average Volume (3M)11.50K
Market Cap
₹98.05B
Enterprise Value₹65.07B
Total Cash (Recent Filing)₹16.78B
Total Debt (Recent Filing)₹902.87M
Price to Earnings (P/E)37.3
Beta1.35
Next Earnings
Aug 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)12.42
Shares Outstanding157,393,980
10 Day Avg. Volume12,021
30 Day Avg. Volume11,497
Financial Highlights & Ratios
PEG Ratio-1.07
Price to Book (P/B)2.15
Price to Sales (P/S)1.64
P/FCF Ratio7.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)23.95
Revenue Forecast (FY)₹49.24B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetThe dramatic reduction in debt-to-equity to near-zero levels and a materially larger equity base provide durable financial flexibility. This lowers refinancing and covenant risk, supports capital spending or capacity additions, and strengthens resilience across industry cycles for multi-month planning horizons.
Material Free Cash Flow GenerationSustained positive operating and free cash flow provides a reliable internal funding source for capex, working capital and strategic investments. Improved cash conversion supports reinvestment in manufacturing capacity and reduces dependence on external financing over the next several quarters.
CDMO Model With Top-line GrowthOperating as a contract development and manufacturing organization offers durable demand from branded and export customers. Recent multi-year revenue growth demonstrates market traction and recurring revenue potential from long-term supply contracts and diversified dosage-form capabilities.
Bears Say
Margin Compression In FY26A material fall in gross and net margins signals structural pressure from cost inflation, adverse product mix, or pricing constraints. If persistent, lower margins reduce free cash flow sustainability and the ability to fund expansion, making profitability more sensitive to volume cycles.
Historically Uneven Cash ConversionPrior years of negative or weak cash conversion show cash generation is variable. Recurring volatility in converting earnings to cash raises risk for consistent capex funding, working capital spikes, and could necessitate external financing during downturns or growth spurts.
Earnings Volatility / EPS ContractionA significant negative EPS growth rate highlights volatility in profitability and earnings sustainability. Persistent swings in EPS complicate long-term planning, undermine confidence in recurring profitability, and increase sensitivity to margin or demand shocks across multi-quarter horizons.
Akums Drugs and Pharmaceuticals Limited News
AKUMS FAQ
What was Akums Drugs and Pharmaceuticals Limited’s price range in the past 12 months?
Akums Drugs and Pharmaceuticals Limited lowest stock price was ₹410.10 and its highest was ₹633.55 in the past 12 months.
What is Akums Drugs and Pharmaceuticals Limited’s market cap?
Akums Drugs and Pharmaceuticals Limited’s market cap is ₹98.05B.
When is Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date?
Akums Drugs and Pharmaceuticals Limited’s upcoming earnings report date is Aug 24, 2026 which is in 70 days.
How were Akums Drugs and Pharmaceuticals Limited’s earnings last quarter?
Akums Drugs and Pharmaceuticals Limited released its earnings results on May 14, 2026. The company reported ₹5.53 earnings per share for the quarter, beating the consensus estimate of N/A by ₹5.53.
Is Akums Drugs and Pharmaceuticals Limited overvalued?
According to Wall Street analysts Akums Drugs and Pharmaceuticals Limited’s price is currently Overvalued.
Does Akums Drugs and Pharmaceuticals Limited pay dividends?
Akums Drugs and Pharmaceuticals Limited pays a N/A dividend of ₹2.7 which represents an annual dividend yield of N/A. See more information on Akums Drugs and Pharmaceuticals Limited dividends here
What is Akums Drugs and Pharmaceuticals Limited’s EPS estimate?
Akums Drugs and Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akums Drugs and Pharmaceuticals Limited have?
Akums Drugs and Pharmaceuticals Limited has 157,393,980 shares outstanding.
What happened to Akums Drugs and Pharmaceuticals Limited’s price movement after its last earnings report?
Akums Drugs and Pharmaceuticals Limited reported an EPS of ₹5.53 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.69%.
Which hedge fund is a major shareholder of Akums Drugs and Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:AKUMS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Akums Drugs and Pharmaceuticals Limited
Akums Drugs & Pharmaceuticals Ltd. is an Indian-based company, established in 2004 and headquartered in Delhi, that operates globally as a manufacturer and supplier of both finished pharmaceutical products and active pharmaceutical ingredients (APIs). Its diverse product range encompasses conventional drugs, traditional Ayurvedic and herbal remedies, personal care items including toiletries, nutraceuticals, food and dietary supplements, dermatological and cosmetic products, and healthcare and hospital supplies, along with over-the-counter (OTC) solutions. The company also deals in excipients and various chemical compounds. Akums develops and markets its own branded formulations across a variety of dosage forms, such as tablets, capsules, injectables, ophthalmic preparations, and soft gelatin capsules. These products address a broad spectrum of therapeutic areas, including gynaecology, cardiology, orthopaedics, pediatrics, dermatology, anti-infectives, pain management, and gastroenterology. Furthermore, Akums Drugs & Pharmaceuticals provides services as a pharmaceutical contract development and manufacturing organization (CDMO).
Technical Analysis
Bafna Pharmaceuticals Limited
―
Bal Pharma Limited
―
Indraprastha Medical Corporation Limited
―
Kopran Limited
―
Wanbury Limited
―